GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apex Biotechnology Corp (TPE:1733) » Definitions » Cyclically Adjusted Revenue per Share

Apex Biotechnology (TPE:1733) Cyclically Adjusted Revenue per Share : NT$22.19 (As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Apex Biotechnology Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Apex Biotechnology's adjusted revenue per share for the three months ended in Mar. 2024 was NT$4.493. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$22.19 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Apex Biotechnology's average Cyclically Adjusted Revenue Growth Rate was 1.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 3.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Apex Biotechnology was 3.40% per year. The lowest was 3.10% per year. And the median was 3.25% per year.

As of today (2024-06-11), Apex Biotechnology's current stock price is NT$33.50. Apex Biotechnology's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was NT$22.19. Apex Biotechnology's Cyclically Adjusted PS Ratio of today is 1.51.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Apex Biotechnology was 1.83. The lowest was 0.95. And the median was 1.23.


Apex Biotechnology Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Apex Biotechnology's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apex Biotechnology Cyclically Adjusted Revenue per Share Chart

Apex Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.86 19.78 20.84 21.78 21.87

Apex Biotechnology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.94 21.97 21.98 21.87 22.19

Competitive Comparison of Apex Biotechnology's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Apex Biotechnology's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apex Biotechnology's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apex Biotechnology's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Apex Biotechnology's Cyclically Adjusted PS Ratio falls into.



Apex Biotechnology Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Apex Biotechnology's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=4.493/131.7762*131.7762
=4.493

Current CPI (Mar. 2024) = 131.7762.

Apex Biotechnology Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 4.328 100.560 5.672
201409 4.179 100.428 5.483
201412 4.724 99.070 6.284
201503 4.531 99.621 5.993
201506 4.137 100.684 5.415
201509 4.798 100.392 6.298
201512 4.450 99.792 5.876
201603 4.479 100.470 5.875
201606 4.857 101.688 6.294
201609 3.213 101.861 4.157
201612 3.700 101.863 4.787
201703 4.262 102.862 5.460
201706 4.004 103.349 5.105
201709 4.762 104.136 6.026
201712 3.574 104.011 4.528
201803 4.706 105.290 5.890
201806 4.555 106.317 5.646
201809 4.968 106.507 6.147
201812 4.622 105.998 5.746
201903 4.659 107.251 5.724
201906 5.040 108.070 6.146
201909 4.765 108.329 5.796
201912 5.859 108.420 7.121
202003 4.521 108.902 5.471
202006 4.943 108.767 5.989
202009 4.631 109.815 5.557
202012 4.005 109.897 4.802
202103 5.096 111.754 6.009
202106 4.528 114.631 5.205
202109 5.091 115.734 5.797
202112 5.548 117.630 6.215
202203 5.187 121.301 5.635
202206 6.068 125.017 6.396
202209 6.055 125.227 6.372
202212 5.040 125.222 5.304
202303 4.342 127.348 4.493
202306 4.170 128.729 4.269
202309 4.140 129.860 4.201
202312 4.104 129.419 4.179
202403 4.493 131.776 4.493

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Apex Biotechnology  (TPE:1733) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Apex Biotechnology's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=33.50/22.19
=1.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Apex Biotechnology was 1.83. The lowest was 0.95. And the median was 1.23.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Apex Biotechnology Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Apex Biotechnology's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Apex Biotechnology (TPE:1733) Business Description

Industry
Traded in Other Exchanges
N/A
Address
No.7, Li-Hsin 5th Road, Hsinchu Science Park, Hsinchu, TWN, 30078
Apex Biotechnology Corp engages mainly in research, development, production, manufacturing and selling of biochemical testing instruments and its detection strips, and trade of products and components relevant to the core business. The company develops and markets biosensor-based blood glucose monitoring systems. The company manufactures non-invasive diagnostic technologies, IT-based telehealth care and molecular diagnostic and traditional Chinese medicine. Its product offerings include Eclipse plus multipurpose analyzer, Glucosure HT blood glucose monitoring system, HemoSmart GOLD hemoglobin screening system among others.

Apex Biotechnology (TPE:1733) Headlines

No Headlines